Biotech & Pharma

Roche to stop work on bone health treatment for Duchenne

24 sec read12 views0 listens

Roche has halted patient recruitment for a Phase 2 trial of Enspryng for Duchenne muscular dystrophy's bone health issues, ending its development for this condition; this decision impacts research directions and funding for treatments in rare diseases, signaling to content creators the importance of staying informed on clinical trial statuses and pharmaceutical company decisions.

Read the full article at Endpoints News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Tech & Gadgets9 hours ago27 sec read

Canada poaches 64 global scholars in bid to bolster domestic talent pipeline

Canada has secured the relocation of 64 international academics, primarily from the U.S., to its universities under a new $1.7 billion initiative aimed at boosting research and innovation in key fields like AI, health, and environmental science. This...

Ali Nemati

Real Estate & Home1 day ago27 sec read

Unstable rental housing creating lifelong disadvantages for children, new study warns

A new study by the Australian Housing and Urban Research Institute reveals that children in rental homes move frequently and are more likely to face poor living conditions, negatively impacting their development. This instability affects physical and...

Ali Nemati

Cybersecurity1 day ago27 sec read

Canadian supercomputers are transforming drug discovery: Can they deliver medicines faster?

Researchers at Simon Fraser University have developed an AI framework called CGFlow, which accelerates the design of drug molecules by ensuring they can be synthesized in a laboratory. This advancement is crucial for reducing the time and cost associ...

Ali Nemati